- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04499495
Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea
A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea
The prevalence of ulcerative colitis (UC), which is one of the inflammatory bowel diseases, is known to be increasing and the majority of patients (≥ 85%) have experienced mild or moderate severity.
5-Aminosalicylic acid (5-ASA), immunomodulator, or biologics, etc are prescribed to treat UC, however 5-ASA is generally considered the first-line therapy. The recent UC treatment guideline in Korea and the United States/ European Union (US/EU) have recommended higher daily dose for patients with mild or moderate severity than the previous guidelines since 2017. Accordingly, it is assumed that the average daily treatment dose of 5-ASA would increase in patients who were initially diagnosed with UC in real-world clinical practice in Korea. However, there are not many studies evaluating the treatment patterns and health outcomes of 5-ASA based on the recent treatment guideline in South Korea.
This study, hence, aims to investigate the impact of changes in daily dose of 5-ASA on the treatment patterns and health outcomes such as recurrence rate, hospitalization rate, and surgery rate in real world practice using Health Insurance Review and Assessment (HIRA) claims database.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Korea, Republic of
- Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who were diagnosed with UC during the index period.
- Patients who had at least two claims of 5-ASA (sulfasalazine, balsalazide, mesalamine) during the index period.
Patients who underwent at least one endoscopy within a 3-month period prior to the index date (i.e. the first date of diagnosis with UC).
- Defined as a claim with relevant endoscopy procedure code.
- Include the upper gastrointestinal endoscopy, colonoscopy, sigmoidoscopy, which are identified using the procedure code.
Patients who were treated with 5-ASA continuously for at least 1-month after the index date.
- Defined as those who were treated with 5-ASA for more than 30 days within 6-month after the index date (i.e. the first date of diagnosis with UC).
Exclusion Criteria:
- Patients less than 15 years old as of the index date (<15 years old).
- Patients who were treated with 5-ASA during the baseline period (i.e. 12-month prior to the index date).
- Patients who were diagnosed with UC during the baseline period.
Patients who received steroids, immunosuppressants, or biologics during the baseline period.
- Steroid includes both oral medication and intravenous (IV) injection. The analysis will include the moderate- to high-dose of cumulative steroid use, which is defined as >=30mg of prednisolone, >= 50mg of methylprednisolone, or >=50mg of hydrocortisone.
- Immunosuppressants is defined as at least one claim with Azathioprine or 6-Mercaptopurine.
- Biologics is defined as at least one claim with Infliximab, Adalimumab, Ustekinumab, Vedolizumab, Golimumab, or Tofacitinib.
Patients who were diagnosed with Crohn's disease at any time in the overall study period.
- Defined as a claim with relevant Crohn's disease code recorded as primary diagnosis during the baseline period or follow-up period (i.e. entire study period).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in initial 3-months average daily dose of 5-ASA
Time Frame: From prescription index date up to 3 months
|
Initial average daily dose is defined as the average dose of 5-ASA prescribed over the 3-month period following the first prescription date of 5-ASA (i.e. prescription index date). Dose of 5-ASA includes those of mesalamine, sulfasalazine, and balsalazide. The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy. Oral and rectal combination therapy will be identified when the percentage of rectal therapy over the 3-months following the first prescription date of 5-ASA is more than 25%. For oral and rectal combination therapy, only oral formulation will be considered to calculate the dose of a combination therapy. The average daily dose of 5-ASA will be categorized as: Oral mono high dose (>=3g), oral mono standard dose (2-3g), oral mono low dose (<2g); Oral combination high dose (>=3g), oral combination standard dose (2-3g); oral combination low dose (<2g); Rectal monotherapy. |
From prescription index date up to 3 months
|
Prescription patterns of 5-ASA
Time Frame: From 01 January 2009 to 31 March 2019
|
The prescription patterns will be categorized into: oral monotherapy; rectal monotherapy; oral and rectal combination therapy based on the exposure medications (mesalazine, sulfasalazine, and/or balsalazide) prescribed.
|
From 01 January 2009 to 31 March 2019
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-response to 5-ASA by the average daily dose of 5-ASA
Time Frame: From 01 January 2009 to 31 March 2019
|
The non-response to 5-ASA is defined as: >=1 claims with international statistical classification of diseases 10th revision (ICD-10) code for UC as primary diagnosis and with pre-defined medications prescribed to those who are not responsive to 5-ASA.
Medications for non-response are defined as add-on or switching to steroids, immunosuppressants, and/or biologics.
|
From 01 January 2009 to 31 March 2019
|
Ulcerative Colitis Related hospitalization by the average daily dose of 5-ASA
Time Frame: From 01 January 2009 to 31 March 2019
|
The hospitalization is defined as: >=1 length of stay (days); admission to the department for gastroenterology; and at least one surgery code or UC medications.
The UC surgery includes small bowel resection, colon resection, and/or low anterior resection, defined using surgery code.
The UC medication is defined as moderate- to high-dose steroids, immunosuppressants, and/or biologics.
|
From 01 January 2009 to 31 March 2019
|
Ulcerative Colitis related surgery by the average daily dose of 5-ASA
Time Frame: From 01 January 2009 to 31 March 2019
|
Surgeries include small bowel resection, colon resection, and/or low anterior resection, which will be identified using surgery code.
|
From 01 January 2009 to 31 March 2019
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Ulcer
- Colitis
- Colitis, Ulcerative
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Anti-Bacterial Agents
- Antitubercular Agents
- Mesalamine
- Aminosalicylic Acid
Other Study ID Numbers
- 000388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
Clinical Trials on PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)
-
Christoph GascheProf. Dr. Gabriela Möslein, Germany; Prof. Dr. Hans Vasen, The Netherlands; Prof... and other collaboratorsTerminatedColorectal CancerNetherlands, Austria, Germany, Israel, Poland, Sweden
-
Warner ChilcottTerminatedUlcerative ColitisUnited States, Canada, Croatia, Russian Federation, Poland, Romania
-
SOFAR S.p.A.Completed
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Sheba Medical CenterCompleted
-
Altheus Therapeutics, Inc.CompletedUlcerative ColitisUnited States
-
University of California, San FranciscoBausch Health Americas, Inc.; California HIV/AIDS Research ProgramCompletedHIV Infections | Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases | Lentivirus Infections | Immune System DiseasesUnited States
-
Merck Sharp & Dohme LLCTerminated
-
Asian Institute of Gastroenterology, IndiaUnknownUlcerative ColitisIndia
-
National Jewish HealthCompleted